Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.
OBJECTIVE: Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in...
| Autors principals: | , , , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
2012
|